Aligos Therapeutics, Inc. Stock Price, News & Analysis

Aligos Therapeutics, Inc. (Nasdaq: ALGS) will present key data at the 32^nd Conference of the Asian Pacific Association for the Study of the Liver (APASL) from February 15-19, 2023, in Taipei, Taiwan. The company will focus on its THR-β agonist, ALG-055009, targeting nonalcoholic steatohepatitis (NASH), with a Phase 2 filing anticipated by year-end. Additionally, insights into its chronic hepatitis B (CHB) portfolio will be showcased. Notable presentations include results on the capsid assembly modulator ALG-000184, highlighting significant reductions in HBsAg levels in patients.

On February 10, 2023, Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced that its CEO, Lawrence M. Blatt, Ph.D., MBA, will present at the SVB Securities Global Biopharma Conference on February 15, 2023, from 5:00 to 5:30 p.m. ET. The conference will be virtual, and a replay of the presentation will be available for 90 days on Aligos' investor website. Aligos is focused on developing therapeutics for nonalcoholic steatohepatitis (NASH) and viral diseases, utilizing its expertise in clinical drug development. The company aims to be a leader in addressing unmet medical needs in these areas.

Aligos Therapeutics (Nasdaq: ALGS) has announced a portfolio reprioritization focusing on its NASH and COVID-19 programs, particularly ALG-055009 and ALG-097558. The company is reducing its workforce by approximately 10% and has seen a total reduction of 25% since January 2022. This strategic shift aims to maintain a strong balance sheet and extend its cash runway until late 2024. Aligos plans to complete clinical studies for its NASH and chronic hepatitis B programs and collaborate with Merck on NASH research. Financial results for Q4 and year-end 2022 will be reported in mid-March 2023.

Aligos Therapeutics (Nasdaq: ALGS) is on track to complete Phase 2-enabling activities for its thyroid hormone receptor beta drug candidate, ALG-055009, for nonalcoholic steatohepatitis by 2023. Initial Phase 1 data shows favorable pharmacokinetics, indicating potentially more predictable dosing across patients compared to leading competitors. The final Phase 1 cohort is expected to finish in H1 2023, while toxicology studies are projected for completion in H2 2023. A comprehensive pipeline update will be discussed at the J.P. Morgan Healthcare Conference on January 12, 2023.

Aligos Therapeutics has initiated dosing of ALG-125755, a small interfering RNA targeting hepatitis B surface antigen (HBsAg), in chronic hepatitis B (CHB) patients as part of Study ALG-125755-501. This advancement follows successful evaluation in healthy volunteers. The company aims to explore various dosing regimens throughout 2023, potentially identifying a combination therapy regimen. Aligos plans to present study data at scientific conferences this year, highlighting their commitment to innovative treatments for viral and liver diseases.

Aligos Therapeutics (ALGS) announced promising progress in the development of its coronavirus protease inhibitor, ALG-097558, during the 2022 Respi DART meeting. The drug demonstrated significant in vivo antiviral activity and effective viral replication inhibition in human cell cultures. First-in-human trials are expected to commence in H1 2023. CEO Lawrence Blatt highlighted ALG-097558's superior potency against SARS-CoV-2, a favorable profile against mutations, and a predicted dosing regimen without the need for ritonavir boosting. The candidate is being developed with international collaboration.

Aligos Therapeutics, Inc. (Nasdaq: ALGS) presented promising data at The Liver Meeting® (November 4-8, 2022) for its drug candidate ALG-055009, a THR-β agonist targeting nonalcoholic steatohepatitis (NASH). The Phase 1 study showed dose-dependent reductions in triglycerides, LDL, and apolipoprotein B after 14 days of administration in hyperlipidemic subjects. The drug was well tolerated, suggesting a favorable pharmacokinetic profile. Aligos aims to start a Phase 2 study assessing the drug's impact on liver fat reduction. Additionally, new data were presented for drug candidates targeting chronic hepatitis B.

Aligos Therapeutics, Inc. (Nasdaq: ALGS) presents promising data from its Phase 1 study of ALG-000184, a small molecule capsid assembly modulator for chronic hepatitis B (CHB). Key results include reductions in hepatitis B surface antigen levels in subsets of subjects, with three out of seven receiving 300 mg showing reductions of 0.2-0.8 log₁₀ IU/mL. Additionally, all subjects exhibited significant declines in HBV DNA (mean decline of 4.2 log₁₀ IU/mL) and RNA levels (mean decline of 3.1 log₁₀ copies/mL). These findings suggest ALG-000184 might have superior antiviral properties, warranting further study.

Aligos Therapeutics (Nasdaq: ALGS) reported Q3 2022 results with a net loss of $18.6 million, improving from $33.1 million in Q3 2021. Cash and investments totaled $142.3 million, projected to fund operations into H1 2024. Progress was noted in drug candidates targeting chronic hepatitis B (CHB), COVID-19, and NASH. The Company observed favorable safety and antiviral activity for ALG-000184 and initiated longer-term dosing cohorts. ALG-125755 is in evaluation with plans for clinical trials in CHB by Q1 2023. Upcoming presentations at The Liver Meeting (AASLD) are anticipated, showcasing positive data.